Relate
Bone Loss |
Evista | |
|
A condition that is characterized by a decrease in bone mass and density, causing bones to become fragile.
|
A drug that belongs to the family of drugs called selective estrogen receptor modulators (SERMs) and is used in the prevention of osteoporosis in postmenopausal women. Raloxifene is also being studied as a cancer prevention drug.
|
Osteoporosis as related to Raloxifene
- Osteoporosis and Raloxifene -- familydoctor.org
Information about osteoporosis and raloxifene from the American Academy of Family Physicians. ... What is osteoporosis? Osteoporosis is a disease that causes bones to break more easily.
- MedlinePlus Medical Encyclopedia: Osteoporosis
Raloxifene (Evista) is another drug used for the prevention and treatment of osteoporosis. Raloxifene is similar to the breast cancer drug tamoxifen. Raloxifene can reduce the risk of spinal fractures ...
- Treating Osteoporosis: Raloxifene
The Women's Health Initiatve trial found that hormone therapy reduced the risk of hip and spine ... Treating Osteoporosis in Postmenopausal Women: A Case Approach - Part 5 . In a large ...
- raloxifene - Menopause: health and medical information produced by ...
This makes bones stronger and prevents fractures in women with osteoporosis. Raloxifene is called a "selective estrogen receptor modulator" since it has effects like estrogen on some ...
- Osteoporosis Treatment
Calcitonin has been shown to slow bone loss, and also decrease pain associated with osteoporosis fractures. Raloxifene Raloxifene is a newer medication that has been developed to provide some of the ...
- Imaginis - Treating Osteoporosis
... topics such as hormone replacement therapy (HRT), heart disease, multiple sclerosis, osteoporosis ... Evista (generic name, raloxifene) belongs to a group of drugs called SERMs (selective estrogen ...
- Raloxifene - Wikipedia, the free encyclopedia
Raloxifene is an oral selective estrogen receptor modulator which is used in the prevention of osteoporosis in postmenopausal women. It was announced on April 17, 2006, that raloxifene is as effective ...
- Raloxifene
Decreases in estrogen levels that are seen after menopause or after removal of the ovaries, lead to a loss of bone density and weakened bones, a condition called osteoporosis. Raloxifene decreases ...
- Osteoporosis Tutorial
In one study risedronate has shown effectiveness in reducing the risk of hip fracture among elderly women with osteoporosis. Raloxifene is a selective estrogen receptor modulator (SERM) that may also ...
- Raloxifene and Osteoporosis - September 15, 1999 - American Academy ...
Please note: This information was as current as we could make it on the date given above. But medical information is always changing, and some information given here may be out of date.

Not Signed In -


